A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry. Click the trial registry identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s). It’s important to appreciate that at the current time, none of these studies is expected to produce a cure for HIV infection—they represent research working toward that goal.
Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases the ATIs are only initiated if certain outcomes are achieved. Table 3 contains completed studies, with links to published or presented results where available. Changes from the previous update are highlighted in yellow. Additional information on current approaches in HIV cure research can be found in TAG’s annual pipeline report. Please send updates, corrections, or suggestions to Richard Jefferys at richard.jefferys@treatmentactiongroup.org.
COVID-19 Update, 8/16/21: The clinical research featured in this listing has been significantly affected by the COVID-19 pandemic. Trials that have yet to begin recruiting may be delayed, and there have been temporary suspensions of enrollment for some ongoing studies. Research is restarting as the situation improves in some areas, but study contacts listed in the individual trial registry entries should be contacted for the latest information. The International AIDS Society (IAS) has issued guidance on mitigation strategies to safely conduct HIV treatment research in the context of COVID-19.
October 15, 2021
Table 1. Current Clinical Trials
|
Trial |
Trial Registry Identifier(s) |
Sponsor(s) |
Phase |
Estimated End Date/Interim |
|
ADOPTIVE IMMUNOTHERAPY |
||||
|
AutoRESIST: HIV |
NCT04975698 |
Catherine Bollard, Children’s |
Phase II |
June 2026 |
|
AlloRESIST: |
Catherine Bollard, Children’s |
Phase I |
April 2024 |
|
|
HST-NEETs: HIV-1 |
Children’s Research Institute |
Phase I |
December 2023 |
|
|
ANTIBODIES |
||||
|
VRC01 (analytical |
HIV Vaccine Trials Network |
N/A |
November 2022 |
|
|
VRC01 (analytical treatment interruption in AMP trial participants) |
HIV Vaccine Trials Network |
N/A |
June 2022 |
|
|
GSK3810109A (broadly neutralizing antibody formerly named N6-LS) |
ViiV Healthcare |
Phase IIa |
November 2023 |
|
|
10-1074-LS + 3BNC117-LS in primary HIV infection |
Imperial College London |
Phase II |
March 2025 |
|
|
UB-421 (antibody inhibitor of HIV binding to CD4 receptors) |
NCT04404049 |
UBP Greater China (Shanghai) Co., Ltd |
Phase II |
June 2024 |
|
UB-421 |
NCT03743376 |
United BioPharma |
Phase II |
December 2021 |
|
vedolizumab (anti-α₄β₇ integrin antibody) |
Ottawa Hospital Research |
Phase II |
December 2021 |
|
|
PGT121 + VRC07-523LS +/- PGDM1400 (broadly neutralizing antibodies) |
International AIDS Vaccine Initiative |
Phase I/IIa |
October 2022 |
|
|
VRC01LS + 10-1074 (broadly |
NCT03707977 |
NIAID |
Phase I/II |
October 2021 |
|
ABBV-382 (anti-α₄β₇ integrin antibody) |
NCT04554966 |
AbbVie |
Phase Ib |
September 2022 |
|
3BNC117 + 10-1074 |
NCT03526848 |
Rockefeller University |
Phase I |
April 2022 |
|
3BNC117-LS + 10-1074-LS in viremic HIV+ individuals |
NCT04250636 |
Rockefeller University |
Phase I |
April 2022 |
|
AAV8-VRC07 (broadly neutralizing antibody |
NIAID
|
Phase I |
March 2027 |
|
|
SAR441236 (tri-specific broadly neutralizing antibody) |
NIAID |
Phase I |
February 2022 |
|
|
VRC01 in acute HIV infection |
NIAID |
Phase I |
March 2021 |
|
|
ANTI-CMV THERAPY |
||||
|
letermovir (Prevymis) |
NCT04840199 |
NIAID |
Phase II |
June 2024 |
|
ANTI-INFLAMMATORY |
||||
|
canakinumab (IL-1β inhibitor) |
NCT02272946 |
University of California, San Francisco |
Phase II |
December 2022 |
|
ANTIRETROVIRAL THERAPY |
||||
|
doravirine concentrations and antiviral activity in cerebrospinal fluid |
NCT04079452 |
Fundacio Lluita Contra la SIDA |
Phase III |
October 2020 |
|
IDOLTIB: Impact of dolutegravir + lamivudine |
University of Liege |
Phase III |
March 2022 |
|
|
CANNABINOIDS |
||||
|
TN-CT11LM, TN-TC19LM oral capsules |
NCT03550352 |
McGill University Health Center |
Phase II |
August 2022 |
|
COMBINATIONS |
||||
|
Perturbing of HIV reservoir with immune stimulation: Fluarix, Pneumovax vaccines |
NCT02707692 |
University of California, San Diego |
Not listed |
January 2022 |
|
MVA.HTI + ChAdOx1.HTI |
NCT04364035 |
Aelix Therapeutics |
Phase IIa |
December 2022 |
|
TITAN: lefitolimod + 3BNC117 + 10-1074 (TLR9 agonist + broadly neutralizing |
University of Aarhus |
Phase IIa |
February 2023 |
|
|
Albuvirtide (fusion |
NCT04819347 |
Frontier Biotechnologies Inc. |
Phase II |
December 2022 |
|
eCLEAR: romidepsin + 3BNC117 |
NCT03041012 |
Aarhus University Hospital |
Phase II |
December 2021 |
|
MVA HIV-B +/- vedolizumab |
NCT04120415 |
French National Agency for |
Phase II |
December 2022 |
|
Research in Viral Eradication of HIV Reservoirs |
NCT02336074 |
Imperial College London
|
Phase II |
November 2022 |
|
UB-421 + chidamide (antibody inhibitor of HIV binding to CD4 receptors + HDAC |
NCT04985890 |
UBP Greater China (Shanghai) Co., |
Phase II |
December 2025 |
|
UB-421 + chidamide |
NCT05056974 |
United |
Phase II |
December 2023 |
|
vorinostat +/- tamoxifen |
NCT03382834 |
NIAID |
Phase II |
June 2023 |
|
Ad26.Mos4.HIV, MVA-BN-HIV, |
NCT04983030 |
Boris Juelg, MD PhD |
Phase I/IIa |
March 2024 |
|
HIVARNA01.3, MVA |
NCT03619278 |
David Garcia Cinca |
Phase I/IIa |
July 2021 |
|
IMPAACT P1115 v2.0: Very |
IMPAACT |
Phase I/II |
December 2031 |
|
|
panobinostat + pegylated |
Massachusetts General Hospital |
Phase I/II |
December 2021 |
|
|
Therapeutic conserved element DNA vaccine (IL-12 adjuvanted p24CE), MVA vaccine boost (MVA/HIV62B), TLR9 agonist (lefitolimod) and broadly neutralizing antibodies (VRC07-523LS + 10-1074) |
UCSF |
Phase I/II |
December 2024 |
|
|
elipovimab (formerly |
GS-US-420-3902 (no clinicaltrials.gov entry) |
Gilead Sciences |
Phase Ib |
N/A |
|
CD4-ZETA gene–modified T |
NCT01013415 |
University of Pennsylvania |
Phase I |
December 2021 |
|
HVRRICANE: HIVIS |
NCT04301154 |
PENTA Foundation |
Phase I |
September 2021 |
|
N-803 (recombinant human super agonist interleukin-15 complex) +/- VRC07-523LS |
NIAID |
Phase I |
August 2023 |
|
|
peginterferon alfa-2b + 3BNC117 + 10-1074 (BEAT-2) |
NCT03588715 |
Wistar Institute |
Phase I |
October 2022 |
|
vorinostat + HXTC: HIV 1 |
Julia Sung, MD, University of North Carolina, |
Phase I |
June 2022 |
|
|
CYTOKINES |
||||
|
N-803 in acute |
Thai Red Cross AIDS Research Centre |
Phase II |
August 2022 |
|
|
Effect of N-803 on B cell |
University of Minnesota |
Phase I |
February 2023 |
|
|
DUAL-AFFINITY RE-TARGETING (DART) MOLECULES |
||||
|
MGD014 |
MacroGenics |
Phase I |
October 2021 |
|
|
GENE THERAPIES |
||||
|
LVgp120duoCAR-T cells |
Steven Deeks, UCSF |
Phase I/IIa |
December 2024 |
|
|
Cal-1: Dual anti-HIV gene transfer construct |
NCT02390297 |
Calimmune |
Phase I/II |
October 2031 |
|
SB-728-T (autologous T cells gene-modified |
Case Western Reserve University |
Phase I/II |
February 2024 |
|
|
AGT103-T (gene-modified HIV-specific CD4 T |
American Gene Technologies International Inc. |
Phase I |
September 2022 |
|
|
CD4 CAR + SB-728mR modified |
University of Pennsylvania |
Phase I |
December 2025 |
|
|
Chimeric Antigen Receptor (CAR)-T |
Guangzhou 8th People’s Hospital |
Phase I |
December 2022 |
|
|
Long-term follow-up of HIV+ participants |
NCT04201782 |
Sangamo Therapeutics |
Phase I |
December 2033 |
|
SB-728mR-HSPC (autologous |
NCT02500849 |
City of Hope Medical Center |
Phase I |
December 2022 |
|
shRNA-modified CD34+ cells |
Shanghai Public Health Clinical Center |
Phase I |
December 2020 |
|
|
TCTIWHI: Third-generation CAR-T-cell therapy |
NCT04863066 |
Beijing 302 Hospital |
Phase I |
October 2022 |
|
GENE THERAPIES FOR HIV-POSITIVE PEOPLE WITH CANCERS |
||||
|
CRISPR CCR5 modified CD34+ cells |
307 Hospital of PLA (Affiliated |
Not listed |
May 2021 |
|
|
Stem cells gene-modified with Cal-1 |
Assistance Publique – Hôpitaux de |
Phase I/II |
January 2024 |
|
|
Stem cells gene-modified with CCR5 |
AIDS Malignancy Consortium |
Phase I/II |
September 2024 |
|
|
Stem cells gene-modified to |
NCT02337985 |
City of Hope Medical Center |
Phase I |
December 2021 |
|
Stem cells gene-modified to |
NCT01961063 |
City of Hope Medical Center |
Phase I |
December 2021 |
|
GONADOTROPIN-RELEASING HORMONE (GnRH) AGONISTS |
||||
|
triptorelin acetate depot |
Immune System Regulation AB |
Phase II |
December 2021 |
|
|
HORMONES |
||||
|
somatotropin (human growth |
McGill University Health Center |
Phase II |
December 2020 |
|
|
IMAGING STUDIES |
||||
|
Imaging immune activation in HIV by PET-MR |
University of California, San Francisco |
Phase I |
October 2021 |
|
|
Radiolabeled VRC01 |
University of California, San Francisco |
Phase I |
October 2021 |
|
|
IMMUNE CHECKPOINT INHIBITORS |
||||
|
durvalumab (anti-PD-L1 antibody) in solid |
NCT03094286 |
Spanish Lung Cancer Group |
Phase II |
April 2022 |
|
budigalimab (anti-PD-1 |
AbbVie |
Phase Ib |
March 2023 |
|
|
budigalimab (anti-PD-1 antibody) |
AbbVie |
Phase I |
December 2021 |
|
|
nivolumab (anti-PD-1 antibody) + |
|
National Cancer Institute (NCI) |
Phase I |
July 2022 |
|
pembrolizumab (anti-PD-1 antibody) |
National Cancer Institute (NCI) |
Phase I |
November |
|
|
pembrolizumab (anti-PD-1 antibody) |
National Institute of Neurological Disorders |
Phase I |
December 2024 |
|
|
LATENCY-REVERSING AGENTS |
||||
|
arsenic trioxide |
Guangzhou 8th People’s Hospital |
Phase I |
December 2022 |
|
|
Euphorbia kansui |
NCT04503928 |
Shanghai Public Health Clinical Center |
Phase I |
December 2022 |
|
Kansui (traditional Chinese medicine |
NCT02531295 |
UCSF |
Phase I |
June 2022 |
|
mTOR INHIBITORS |
||||
|
metformin |
University of Hawaii |
Phase II/III |
December 2022 |
|
|
PROTEASOME INHIBITORS |
||||
|
ixazomib |
NCT02946047 |
Mayo Clinic |
Phase I |
January 2022 |
|
STEM CELL TRANSPLANTATION |
||||
|
IMPAACT P1107: Cord blood |
(closed to enrollment) |
International Maternal Pediatric Adolescent |
N/A |
November 2021 |
|
Cord blood transplant with OTS for the |
Fred Hutchinson Cancer Research Center |
Phase II |
December 2025 |
|
|
STIMULANTS |
||||
|
EMRLHD: Effect of methamphetamine on residual |
University of California, San Francisco |
Phase IV |
June 2022 |
|
|
THERAPEUTIC VACCINES |
||||
|
BELIEVE: BCG |
NCT05004038 |
University of Zurich |
Phase IIa |
January 2024 |
|
Ad26.Mos4.HIV + |
NCT03307915 |
Janssen Vaccines & Prevention B.V. |
Phase I |
November 2021 |
|
DC-HIV04: a1DC + |
Sharon Riddler, University of Pittsburgh |
Phase I |
May 2023 |
|
|
DNA.HTI + |
NCT04385875 |
Fundacio Lluita Contra la SIDA |
Phase I |
June 2022 |
|
MVA.tHIVconsv3 |
University of North Carolina, Chapel Hill |
Phase I |
June 2022 |
|
|
NETI: |
Madhuchhanda Choudhary |
Phase I |
September 2024 |
|
|
TREATMENT INTENSIFICATION/EARLY TREATMENT |
||||
|
P25-INACTION: |
Adriano Lazzarin, MD |
Phase IV |
June 2021 |
|
|
Antiretroviral regime for viral eradication |
NCT02712801 |
National Center for Women and Children’s |
Phase IV |
December 2022 |
|
DGVTAF: Immediate initiation of antiretroviral |
NCT02656511 |
UCSF |
Phase IV |
April 2023 |
|
AAHIV: Antiretroviral |
South East Asia Research Collaboration with |
Phase III |
June 2033 |
|
|
EIT: Early infant HIV treatment in Botswana |
NCT02369406 |
Harvard School of Public Health |
Phase II/III |
May 2022 |
|
EARLIER: Early ART to limit infection and |
NCT02859558 |
AIDS Clinical Trials Group |
Phase II |
September 2023 |
Table 2. Observational Studies
|
Trial |
Trial Registry Identifier(s) |
Manufacturer/ |
Phase |
Estimated End Date/Interim |
|
2000HIV: 2000 HIV human functional genomics partnership |
Radboud University |
N/A |
December 2023 |
|
|
2000HIVTrained: 2000 HIV trained |
NCT04968717 |
Radboud University |
N/A |
December 2022 |
|
Accurate staging of immuno-virological |
University Hospital, Ghent |
N/A |
January 2023 |
|
|
Analytic treatment interruption |
NCT02437526 |
Mayo Clinic |
N/A |
|
|
ANRS CO24 OncoVIHAC: Immune checkpoint |
Inserm-ANRS |
N/A |
June 2022 |
|
|
ATGALIG-HIV: Study of autophagy and the effects |
Centre Hospitalier Régional d’Orléans |
N/A |
November 2029 |
|
|
CHRONO: A prospective cohort for ex vivo cure |
Erasmus Medical Center |
N/A |
January 2034 |
|
|
CODEX (the “Extreme” cohort, ANRS CO21) |
Inserm-ANRS |
N/A |
September 2023 |
|
|
Developing a functional cure for HIV disease: |
American Gene Technologies International Inc. |
N/A |
February 2021 |
|
|
DOLUVOIR: Cartography of virologic reservoir |
Inserm-ANRS |
N/A |
February 2021 |
|
|
Establish and characterize an acute HIV |
Southeast Asia Research Collaboration with |
N/A |
July 2033 |
|
|
Evaluation of the role of HIV-1 Tat protein |
Barbara Ensoli, MD, PhD, Istituto Superiore |
N/A |
December 2023 |
|
|
FRESH (Females rising through education, support, |
Ragon Institute |
Ragon Institute of MGH, MIT and Harvard |
N/A
|
|
|
HEATHER: HIV reservoir targeting with early |
UK CPMS17589 |
University of Oxford/Medical Research |
N/A |
September 2019 |
|
HIV-Mercuri: HIV study on measuring the reservoir |
University Hospital, Ghent |
N/A |
December 2025 |
|
|
Host & viral factors associated with HIV |
UK CPMS16146 |
University College London Hospitals NHS |
N/A |
May 2021 |
|
HSCT-HIV: Allogeneic hematopoietic stem cell |
Kirby Institute |
N/A |
September 2024 |
|
|
HUSH restriction in HIV+ patients |
Inserm-ANRS |
N/A |
September 2022 |
|
|
iCHIP: Effect of immune checkpoint inhibitors on |
hivcure.com.au (no registry entry) |
University of Melbourne |
N/A |
N/A |
|
IciStem: |
IciStem website (no clinicaltrials.gov |
amfAR |
N/A |
N/A CROI 2020, Abstract 339 |
|
Identification and quantification of HIV CNS |
St Vincent’s Hospital, Sydney
|
N/A |
December 2020 |
|
|
Impact of ART adherence on HIV persistence |
NCT02797093 |
University of Colorado, Denver |
N/A |
October 2021 |
|
Investigation of the impact of inducible, |
Kenya Medical Research Institute |
N/A |
April 2022 |
|
|
Long-term effects of ART in acute HIV |
Key Laboratory of AIDS Immunology of National |
N/A |
June 2021 |
|
|
Measurement for viral reservoir and immune |
National Taiwan University Hospital |
N/A |
December 2021 |
|
|
PITCH: |
NHS Health Research |
University of Oxford |
N/A |
N/A |
|
Post analytic treatment interruption study |
South East Asia Research Collaboration with |
N/A |
March 2031 |
|
|
PRIMO (ANRS CO6): Primary infection cohort |
Inserm-ANRS |
N/A |
December 2022 |
|
|
Quantitative measurement and correlates of |
NCT02154035 |
NIAID |
N/A |
January 2022 |
|
RESERVIH32: Bioclinical evaluation of two |
Centre Hospitalier Universitaire de Nīmes |
N/A |
September 2022 |
|
|
Role of the IL-33/amphiregulin pathway as a |
Inserm-ANRS |
N/A |
September 2023 |
|
|
Saturne-HIV: Sequential analysis before and after |
University Hospital, Ghent |
N/A |
January 2025 |
|
|
SCOPE-ATI: SCOPE analytic treatment interruption protocol |
NCT04359186 |
UCSF |
N/A |
June 2024 |
|
TESOVIR: |
Centre Hospitalier Régional |
N/A |
September 2022 |
|
|
The Gemini Study: Safety and survival of |
NCT04799483 |
NIAID |
N/A |
January 2030 |
|
The Last Gift Study (for people with HIV and |
University of California, San Diego (UCSD) |
N/A |
N/A |
|
|
The use of leukapheresis to support HIV |
University of California, San Francisco |
N/A |
December 2022 |
|
|
Thinking and memory problems in people with |
National Institute of Neurological Disorders |
N/A |
February 2037 |
|
|
TRESAX: T follicular helper reservoir in axillary |
hivcure.com.au (no registry entry) |
Kirby Institute |
N/A |
N/A |
Table 3. Completed Studies
|
Trial |
Trial Registry Identifier(s) |
Manufacturer/ |
Phase |
Published/Presented Data |
|
ADOPTIVE IMMUNOTHERAPY |
||||
|
Early ART in combination with |
Yongtao Sun, MD, PhD, Tangdu |
Phase III |
N/A |
|
|
Reconstitution of HIV-specific |
Guangzhou 8th People’s Hospital |
Phase I/II |
N/A |
|
|
HIV-specific memory CD8 T cells |
Beijing You’an Hospital, Capital |
Phase I |
||
|
HXTC: HIV 1 |
University of North Carolina, |
Phase I |
||
|
ANTIBODIES |
||||
|
3BNC117 (broadly neutralizing monoclonal |
Rockefeller University |
Phase II |
||
|
3BNC117 |
Rockefeller University |
Phase II |
N/A |
|
|
UB-421 (antibody inhibitor of HIV binding to |
United BioPharma |
Phase II |
||
|
vedolizumab (anti-α₄β₇ |
Hospitales Universitarios Virgen del Rocío |
Phase II |
||
|
VRC01 (broadly neutralizing monoclonal antibody) |
National Institute of Allergy and Infectious |
Phase II |
Lancet |
|
|
VRC01 (broadly neutralizing antibody) in |
NIAID |
Phase I/II |
N/A |
|
|
10-1074 (broadly neutralizing monoclonal |
Rockefeller University |
Phase I |
||
|
10-1074-LS + 3BNC117-LS (long-acting broadly neutralizing |
Rockefeller University |
Phase I |
N/A |
|
|
3BNC117 |
Rockefeller University |
Phase I |
||
|
3BNC117 + 10-1074 |
NIAID |
Phase I |
N/A |
|
|
3BNC117 + 10-1074 |
Rockefeller University |
Phase I |
||
|
3BNC117-LS |
Rockefeller University |
Phase I |
N/A |
|
|
CHERUB 001 |
No clinicaltrials.gov entry |
CHERUB (Collaborative HIV Eradication of |
N/A |
|
|
elipovimab (formerly GS-9722; PGT121-derived |
GS-US-420-3902 Adisinsight entry |
Gilead Sciences |
Phase I |
CROI 2020, Abstract 39, Webcast |
|
PGDM1400 +/– PGT121 +/– VRC07-523LS (broadly |
International AIDS Vaccine Initiative |
Phase I |
N/A |
|
|
PGT121 |
International AIDS Vaccine Initiative |
Phase I |
Nat Med. 2021 Oct |
|
|
vedolizumab |
NIAID |
Phase I |
AIDS 2018, WESS0102 |
|
|
VRC01 + 10-1074 |
NIAID |
Phase I |
N/A |
|
|
VRC01 |
NIAID |
Phase I |
N/A |
|
|
VRC01 |
NIAID |
Phase I |
||
|
VRC01 |
NIAID |
Phase I |
N Engl J Med. 2016 |
|
|
VRC01 |
NIAID |
Phase I |
||
|
VRC01LS, VRC07-523LS (long-acting broadly neutralizing |
NIAID |
Phase I |
IAS 2019, Abstract WEAA0305LB (video, at 45:36) |
|
|
ANTI-FIBROTIC |
||||
|
ACE inhibitors |
UCSF/amfAR |
Phase IV |
||
|
losartan |
University of Minnesota |
Phase II |
CROI 2020, Abstract 277 |
|
|
telmisartan |
AIDS Clinical Trials Group |
Phase II |
CROI 2019, Abstract 395 |
|
|
telmisartan |
Yale University |
Phase I |
CROI 2019, Abstract 300 |
|
|
ANTI-INFLAMMATORY |
||||
|
CD24Fc (human CD24 extracellular domain and human |
OncoImmune, Inc. |
Phase II |
“Terminated (Business Reasons)” |
|
|
High dose vitamin D supplementation |
University of Melbourne |
Phase II |
N/A |
|
|
CC-11050 (phosphodiesterase-4 inhibitor) |
NIAID |
Phase I |
AIDS 2018, Poster abstract |
|
|
ANTI-PROLIFERATIVE |
||||
|
mycophenolate mofetil (MMF) |
Fred Hutchinson Cancer Research Ctr |
Phase I |
CROI 2020, Abstract 340 |
|
|
ANTIRETROVIRAL THERAPY |
||||
|
dolutegravir in reservoirs |
Emory University |
Phase IV |
||
|
HIV reservoir dynamics after switching to |
Hospital Universitari Vall d’Hebron Research |
Phase IV |
N/A |
|
|
raltegravir or efavirenz + tenofovir + emtricitibine |
University of Alabama at Birmingham |
Phase IV |
N/A |
|
|
ABX464 |
Abivax S.A. |
Phase II |
||
|
ABX464 |
Abivax S.A. |
Phase I/II
|
Clin Infect Dis. 2021 16th European Meeting on HIV & Hepatitis |
|
|
ANTIRETROVIRAL THERAPY IN HIV CONTROLLERS |
||||
|
emtricitabine + rilpivirine |
AIDS Clinical Trials Group/NIAID |
Phase IV |
J Infect Dis. 2020 |
|
|
raltegravir + tenofovir + emtricitabine |
University of California, San Francisco |
Phase IV |
||
|
ASSEMBLY INHIBITORS |
||||
|
BIT225 |
Biotron Limited |
Phase II |
J Infect Dis. |
|
|
BIT225 |
Biotron Limited |
Phase I |
||
|
COMBINATIONS |
||||
|
maraviroc, dolutegravir, |
Federal University of São Paulo |
Not listed |
AIDS 2020, Abstract OAXLB0105 |
|
|
ROADMAP: romidepsin |
Rockefeller University |
Phase IIa |
CROI 2020, Abstract 38, Webcast |
|
|
Adoptive transfer of haploidentical |
University of Minnesota – Clinical and |
Phase II |
N/A |
|
|
ERAMUNE-01 |
ORVACS/Cytheris SA/Merck Sharp & Dohme |
Phase II |
||
|
ERAMUNE-02 (DNA/Ad5 vaccine, ART intensification) |
|
Vical/GenVec/CHERUB/NIH Vaccine Research |
Phase II |
Lancet HIV. 2015 CROI 2014, Poster abstract 422 |
|
disulfiram + vorinostat |
NCT03198559 |
The Peter Doherty Institute for Infection and |
Phase I/II |
AIDS. |
|
GTU-MultiHIV B-clade + MVA HIV-B +/- |
Inserm-ANRS |
Phase I/II |
Terminated due to the bankruptcy of |
|
|
Vacc-4x |
Bionor Immuno AS/Celgene |
Phase I/II
|
CROI 2019, Abstract 397 |
|
|
Vacc-4x |
Bionor Immuno AS |
Phase I/II |
IAS 2015 Towards an HIV Cure Symposium, Poster abstract PE61 |
|
|
vorinostat + hydroxychloroquine + maraviroc |
NCT02475915 |
South East Asia Research Collaboration with |
Phase I/II |
J Virus Erad. 2020 (6) |
|
Adoptive transfer of haploidentical |
University of Minnesota – Clinical and |
Phase I |
N/A |
|
|
AGS-004 + vorinostat |
NIAID |
Phase I |
Sci Rep. 2020 Mar |
|
|
chemotherapy + |
Fundacion para la Investigacion Biomedica del |
Phase I |
Terminated due to futility criteria |
|
|
Chidamide + CAR-T |
Guangzhou 8th People’s Hospital |
Phase I |
N/A |
|
|
DCV3 |
Judit Pich Martínez, Fundació |
Phase I |
CROI 2020, Abstract 282 |
|
|
MVA-B (viral |
Hospital Clinic of |
Phase I |
||
|
MVA.HIVconsv |
IrsiCaixa |
Phase I
|
J Antimicrob |
|
|
VRC07-523LS + vorinostat |
University of North Carolina, Chapel Hill |
Phase I |
J |
|
|
CYTOKINES |
||||
|
interleukin-2 (IL-2) |
Case Western Reserve University |
Phase II |
N/A |
|
|
N-803 |
University of Minnesota – Clinical and |
Phase I |
CROI 2018, Poster abstract 356 |
|
|
GENE THERAPIES |
||||
|
OZ1 |
Janssen-Cilag Pty Ltd |
Phase II |
||
|
Cal-1: Dual anti-HIV gene transfer construct |
Calimmune |
Phase I/II |
N/A
|
|
|
SB-728mR-T (autologous CD4 T cells genetically |
Sangamo BioSciences |
Phase I/II |
N/A |
|
|
SB-728-T + |
Sangamo BioSciences |
Phase I/II
|
CROI 2016, Poster abstract 358LB CROI 2015, Poster abstract 434 CROI 2014, Abstract 141, Webcast |
|
|
SB-728-T |
Sangamo BioSciences |
Phase I/II |
N/A |
|
|
VRX496 (gene-modified autologous CD4 T cells) |
University of Pennsylvania |
Phase I/II |
||
|
C34-CXCR4 (autologous CD4 T cells gene-modified |
University of Pennsylvania
|
Phase I |
N/A |
|
|
HGTV43 |
No clinicaltrials.gov entry |
Enzo Biochem |
Phase I |
AIDS 2006, Abstract MOPDA06 |
|
MazF-T (redirected MazF-CD4 autologous T cells) |
Takara Bio/University of Pennsylvania |
Phase I |
Molecular Therapy, |
|
|
Redirected high affinity Gag-specific T cells |
University of Pennsylvania/Adaptimmune |
Phase I |
Study closed due to safety concern, see: Mol Ther. 2015 Jul; |
|
|
SB-728mR-T + |
University of Pennsylvania |
Phase I |
J Clin Invest. 2021. |
|
|
SB-728-T |
Sangamo BioSciences |
Phase I |
ICAAC 2014, Abstract H-643; 2013, Abstract |
|
|
SB-728-T
|
Sangamo Biosciences/University of |
Phase I |
||
|
GENE THERAPIES FOR HIV-POSITIVE PEOPLE WITH CANCERS |
||||
|
Stem cells gene-modified with M87o vector |
Universitätsklinikum Hamburg-Eppendorf |
Phase I/II |
N/A |
|
|
Stem cells gene-modified to encode multiple |
City of Hope Medical Center |
Phase I |
||
|
IMAGING STUDIES |
||||
|
123I radiolabeled 3BNC117 |
University of Lausanne Hospitals |
Phase I |
N/A |
|
|
Radiolabeled 3BNC117 + Copper-64 radio |
Bayside Health |
Phase I |
EBioMedicine. 2021 |
|
|
IMMUNE CHECKPOINT INHIBITORS |
||||
|
cemiplimab (anti-PD-1 antibody) |
NIAID |
Phase I/II |
Pre-CROI Community HIV Cure Research Workshop |
|
|
BMS-936559 (anti-PD-L1 antibody) |
National Institute of Allergy and Infectious |
Phase I |
J Infect Dis. 2017 CROI 2016, Abstract 25, Webcast |
|
|
ipilimumab (anti-CTLA-4 antibody) |
Medarex |
Phase I |
||
|
IRON CHELATORS |
||||
|
deferiprone |
ApoPharma |
Phase I |
N/A |
|
|
JANUS KINASE INHIBITORS |
||||
|
ruxolitinib |
NIAID |
Phase II |
J Clin Pharmacol. |
|
|
LATENCY-REVERSING AGENTS |
||||
|
disulfiram |
University of California, San Francisco/ |
Not specified |
||
|
Chidamide |
Tang-Du Hospital |
Phase II/III |
N/A |
|
|
vorinostat (HDAC inhibitor) |
Bayside Health/Merck |
Phase II |
||
|
valproic acid (HDAC inhibitor) |
McGill University/Canadian Foundation for |
Phase II |
||
|
valproic acid |
University of North Carolina at Chapel |
Phase II
|
||
|
Chidamide (HDAC inhibitor) |
Tang-Du Hospital |
Phase I/II |
HIV Med. 2020 |
|
|
disulfiram (acetaldehyde dehydrogenase |
University of California, San |
Phase I/II |
CROI 2015, Poster abstract 428LB |
|
|
panobinostat (HDAC |
University of Aarhus/ |
Phase I/II |
CROI 2015, Abstract 109, Webcast |
|
|
romidepsin (HDAC inhibitor) |
AIDS Clinical Trials Group/NIAID/Gilead |
Phase I/II
|
The Journal of |
|
|
valproic acid + pyrimethamine |
Erasmus Medical Center |
Phase I/II |
N/A |
|
|
vorinostat |
University of North Carolina at Chapel Hill/NIAID/Merck |
Phase I/II |
J Clin Invest. 2017 Aug 1;127(8):3126-3135. |
|
|
bryostatin 1 (PKC agonist) |
Fundacion para la Investigacion Biomedica del |
Phase I |
||
|
mTOR INHIBITORS |
||||
|
Impact of Everolimus on HIV |
UCSF |
Phase IV |
||
|
Sirolimus |
ACTG |
Phase I/II |
CROI 2019, Abstract 131, Webcast |
|
|
metformin |
McGill University Health Center |
Phase I |
EBioMedicine 65 |
|
|
OBSERVATIONAL STUDIES |
||||
|
ACTG A5321: Decay of HIV-1 reservoirs in |
N/A |
AIDS Clinical Trials Group |
N/A
|
CROI 2021, Abstract 241, Webcast CROI 2018, Abstract 119, Webcast |
|
ANRS EP 44: Residual replication |
Inserm-ANRS |
N/A |
N/A |
|
|
ANRS EP63: A chronological study of the |
Inserm-ANRS |
N/A |
N/A |
|
|
APACHE: |
Ospedale San Raffaele |
N/A |
Viruses. 2021 Jul 19;13(7):1403. J Antimicrob |
|
|
Biomarkers to predict time to |
AIDS Clinical Trials Group |
N/A |
Clin Infect Dis. 2021 |
|
|
CHERUB 003 |
Imperial College London/CHERUB |
N/A |
N/A |
|
|
CLEAC: Comparison of late versus early |
Inserm-ANRS |
N/A |
Front Immunol. 2021 |
|
|
Effects of dolutegravir based regimen on |
University Hospital, Strasbourg, France |
N/A |
||
|
EPIC4: Early Pediatric Initiation: Canada Child |
Canadian Institutes of Health Research |
N/A
|
Clin Infect Dis. 2019 |
|
|
EURECA: Exploratory study of cellular reservoirs in |
Centre Hospitalier Universitaire de Besancon |
N/A |
||
|
FXReservoir: Study of the effects of farnesoid X |
Hospices Civils de Lyon |
N/A |
N/A |
|
|
Genotyping FcɣRs genes |
University Hospital, Strasbourg, France |
N/A |
||
|
HCURE: Analysis of the impact of HCV direct |
Assistance Publique Hopitaux De Marseille |
N/A |
N/A |
|
|
HIV-PRADA: HIV persistence in lymph node and |
University of Melbourne |
N/A |
CROI 2021, Abstract 301, Webcast |
|
|
HIV resistance and treatment strategies |
NIAID |
N/A |
N/A |
|
|
HIV-STAR: HIV |
University Hospital, Ghent
|
N/A |
IAS 2021, Abstract PEA036 (poster, video) |
|
|
ImmunoCo27: Co-adaptation between HIV and CD8 |
Inserm-ANRS |
N/A |
N/A |
|
|
IMPAACT 2015: Evaluation of the |
IMPAACT |
N/A |
N/A |
|
|
Impact of a short-term ATI and |
NIAID |
N/A |
||
|
In vitro autologous vaccine development to |
UK CPMS17532 (link currently broken) |
Imperial College London/amfAR |
N/A |
N/A |
|
ISALA: Analytical |
Institute of Tropical Medicine, |
N/A |
J Int AIDS Soc. 2020 |
|
|
LoViReT: Low viral reservoir treated patients |
IrsiCaixa |
N/A |
EBioMedicine. 2020 |
|
|
MUCOVIR: Exploration of HIV reservoirs |
Objectif Recherche Vaccins SIDA |
N/A |
||
|
PembroHIV: Treatment with immunological |
IrsiCaixa |
N/A |
HIV Persistence Workshop 2019, Abstract PP |
|
|
Role of anti-Tat immunity on disease |
National HIV/AIDS Research Center |
N/A |
||
|
Role of anti-Tat immunity on disease |
CNAIDS, Istituto Superiore di Sanità, Rome, Italy |
N/A |
||
|
Seroprevalence of anti-Tat antibodies in |
CNAIDS, Istituto Superiore di Sanità, Rome, Italy |
N/A |
N/A |
|
|
Size of the HIV-1 reservoir and ongoing |
UK CPMS16004 (link currently broken) |
University College London/amfAR |
N/A |
N/A |
|
Specimen repository for HIV |
AIDS Healthcare Foundation |
N/A |
N/A |
|
|
Tissue drug levels of HIV medications |
University of Minnesota – Clinical and |
N/A |
||
|
ULTRASTOP (Towards |
Objectif Recherche VACcin Sida |
N/A |
||
|
VIRECT: Impact of pre-ART CD4 T cell level on the |
Centre Hospitalier Universitaire de Saint |
N/A |
N/A |
|
|
STEM CELL TRANSPLANTATION |
||||
|
HIVECT: HIV |
Puerta de Hierro University |
N/A |
N/A |
|
|
BMT CTN 0903: Allogeneic transplant |
National Heart, Lung, & Blood |
Phase II |
Biol Blood Marrow |
|
|
HLA-mismatched unrelated donor bone marrow |
Center for International Blood and Marrow |
Phase II |
HRSA Advisory Council |
|
|
Immune response after stem cell transplant in |
Fred Hutchinson Cancer Research Center |
Phase II |
N/A |
|
|
Optimized antiretroviral therapy during |
Sidney Kimmel Comprehensive Cancer Center at |
Phase I |
AIDS Res Hum |
|
|
THERAPEUTIC VACCINES |
||||
|
AGS-004 |
Argos Therapeutics |
Phase IIb |
||
|
AGS-004 |
Argos Therapeutics |
Phase IIb |
AIDS Res Hum IAS 2015 Towards an HIV Cure CROI 2014, Poster abstract 344 |
|
|
iHIVARNA-01 |
Rob Gruters, Erasmus Medical |
Phase IIa |
||
|
DermaVir (topically applied DNA vaccine) |
Genetic Immunity |
Phase II |
N/A |
|
|
DermaVir |
Genetic Immunity |
Phase II
|
N/A |
|
|
GSK Biologicals HIV Vaccine 732462 (p24-RT-Nef-p17 |
GlaxoSmithKline |
Phase II |
||
|
GTU-multiHIV + |
Inserm-ANRS |
Phase II
|
J Infect Dis. 2019 |
|
|
Tat protein vaccine |
NCT01513135 |
CNAIDS, Istituto Superiore di Sanità, Rome, Italy |
Phase II |
|
|
Tat protein vaccine |
NCT00751595 |
Barbara Ensoli, MD, Istituto Superiore di |
Phase II |
Front. Immunol. |
|
Vacc-4x (peptide-based |
Bionor Immuno AS |
Phase II |
||
|
Vacc-4x |
Bionor Immuno AS |
Phase II |
||
|
VAC-3S |
InnaVirVax |
Phase II |
NPJ Vaccines (2019) |
|
|
VAC-3S |
InnaVirVax |
Phase I/IIa |
N/A |
|
|
VAC-3S (peptide-based |
InnaVirVax |
Phase I/IIa |
IAS 2015 Towards an HIV Cure Symposium, Poster abstract PE67 30 Years of HIV Science, 2013, Poster abstract 145 |
|
|
AGS-004 |
University of North Carolina at Chapel |
Phase I/II |
N/A |
|
|
Autologous |
Sharon Riddler, University of |
Phase I/II |
||
|
Dendritic cells |
University of Sao Paulo General Hospital |
Phase I/II |
||
|
Dendritic cell |
Massachusetts General Hospital |
Phase I/II |
N/A |
|
|
Dendritic |
Hospital Clinic of Barcelona |
Phase I/II |
||
|
DermaVir |
AIDS Clinical Trials Group |
Phase I/II |
||
|
GTU®-MultiHIV B clade |
Imperial College London |
Phase I/II |
||
|
p24CE1/2 + p55^gag |
NIAID |
Phase I/II |
N/A |
|
|
PENNVAX-GP or |
Steven Deeks, UCSF |
Phase I/II |
N/A |
|
|
Tat Oyi (protein-based |
Biosantech |
Phase I/II |
||
|
THV01 |
Theravectys S.A. |
Phase I/II |
N/A |
|
|
TUTI-16 (synthetic |
Thymon, LLC |
Phase I/II |
||
|
Vacc-C5 (peptide-based |
Bionor Immuno AS |
Phase I/II |
||
|
Ad26.Mos.HIV + |
Janssen Vaccines & Prevention B.V. |
Phase I |
Nat Med March 23, |
|
|
AFO-18 (peptide-based |
Statens Serum Institut (SSI)/Ministry of the |
Phase I |
||
|
AFO-18 (peptide-based |
SSI/Rigshospitalet/Hvidovre University |
Phase I |
||
|
AT20-KLH |
MED-AT20-001 |
Medestea Research & Production SpA, Turin |
Phase I |
|
|
ChAdV63.HIVcons + MVA.HIVconsv |
IrsiCaixa/Fundació Lluita contra la |
Phase I |
EClinicalMedicine. |
|
|
Dendritic |
Baylor Research Institute/ANRS |
Phase I |
PLoS Pathog. 2019 Sep |
|
|
DermaVir |
Genetic Immunity |
Phase I |
||
|
D-GPE DNA + M-GPE MVA (DNA + viral |
Centers for Disease Control and Prevention, |
Phase I |
N/A |
|
|
DNA.HTI + |
Aelix Therapeutics |
Phase I |
CROI 2021, Abstract 161, Webcast |
|
|
HIVAX |
GeneCure Biotechnologies |
Phase I |
Vaccine. 2020 May |
|
|
HIV-v (peptide-based |
PepTcell Limited |
Phase I |
||
|
iHIVARNA-01 (TriMix |
Biomedical Research Institute August Pi i |
Phase I |
||
|
JS7 DNA + |
GeoVax, Inc. |
Phase I |
||
|
MAG pDNA vaccine +/- IL-12 |
NIAID |
Phase I |
||
|
MAG-pDNA + |
NIAID/Profectus Biosciences, Inc. |
Phase I |
J. Virology May 20, |
|
|
MVA.HIVconsv |
University of Oxford/Medical Research Council |
Phase I |
N/A |
|
|
PENNVAX-B (Gag, Pol, |
Inovio Pharmaceuticals |
Phase I |
||
|
PENNVAX-B +/- |
University of Pennsylvania |
Phase I |
N/A |
|
|
Recombinant |
Centers for Disease Control and Prevention, |
Phase I |
N/A |
|
|
rMVA-HIV + rFPV-HIV (viral vector |
NIAID |
Phase I |
||
|
Tat protein vaccine |
NCT00505401 NCT01024595 (extended follow-up |
CNAIDS, Istituto Superiore di Sanità, Rome, Italy |
Phase I
|
Rev Recent Clin Trials. 2009 Sep;4(3):195-204 Vaccine. 2009 May |
|
TOLL-LIKE RECEPTOR AGONISTS |
||||
|
MGN1703 toll-like receptor 9 (TLR-9) agonist |
University of Aarhus |
Phase Ib/IIa |
EBioMedicine. 2019 |
|
|
Poly-ICLC (TLR-3 agonist) |
Nina Bhardwaj, MD/Campbell |
Phase I/II |
||
|
vesatolimod (TLR-7 |
Gilead Sciences |
Phase Ib |
IAS 2021, Abstract OAA0304 (video) CROI 2020, Abstract 40, Webcast |
|
|
vesatolimod (formerly GS-9620) (TLR-7 agonist) |
Gilead Sciences |
Phase Ib |
Clinical Infectious |
|
|
TRADITIONAL CHINESE MEDICINE |
||||
|
Triptolide wilfordii |
Peking Union Medical College |
Phase III |
N/A |
|
|
TREATMENT INTENSIFICATION/EARLY TREATMENT |
||||
|
enfuvirtide |
NIAID |
Not listed |
||
|
enfuvirtide |
Canadian Immunodeficiency Research |
Not listed |
N/A |
|
|
New Era Study: Treatment with |
MUC Research GmbH |
Not listed |
||
|
PLUS: Pilot |
University of California, San Francisco |
Not listed
|
||
|
Anti-HIV medications |
NIAID |
Phase IV |
||
|
DIORR: Dolutegravir impact on residual replication |
University of Melbourne |
Phase IV |
The Lancet HIV, CROI 2018, Abstract 71, Webcast |
|
|
DRONE: Impact of starting a dolutegravir-based |
University Hospital, Strasbourg, France |
Phase IV |
N/A |
|
|
LEOPARD: Latency |
Columbia University |
Phase IV |
Clinical Infectious |
|
|
ANRS 147 OPTIPRIM: Optimization of |
Inserm-ANRS |
Phase III |
PLoS One. 2013; 8(3): IAS Cure Symposium 2013, Presentation |
|
|
maraviroc |
Germans Trias i Pujol Hospital |
Phase III |
||
|
raltegravir + |
Centre Hospitalier Intercommunal de Toulon La |
Phase III |
N/A |
|
|
raltegravir |
Germans Trias i Pujol Hospital |
Phase III |
||
|
tenofovir/emtricitabine + dolutegravir |
Inserm/ANRS |
Phase III |
N/A |
|
|
VIRECURE: Impact of extremely early ART to |
David Garcia Cinca, Hospital Clinic of |
Phase III |
N/A |
|
|
Intense acute infection study |
University of Toronto |
Phase II/III |
N/A |
|
|
maraviroc |
Fundación para la Investigación Biomédica del |
Phase II |
||
|
peginterferon alfa-2a (Pegasys) |
Wistar Institute |
Phase II |
EBioMedicine. 2020 Aug 19;59:102945. |
|
|
peginterferon alfa-2b |
University of Pennsylvania/Wistar |
Phase II |
AIDS Res Hum |
|
|
peginterferon alfa-2b |
Wistar Institute |
Phase II |
HIV Persistence Workshop 2019, |
|
|
raltegravir |
Canadian Immunodeficiency Research |
Phase II |
||
|
raltegravir |
Fundación para la Investigación Biomédica del Hospital |
Phase II |
||
|
Viral suppression after analytic treatment |
South East Asia Research Collaboration with |
Phase II |
Nat Med. 2018 Jun 11 CROI 2017, Abstract 124, Webcast |
|
|
alpha interferon intensification |
NIAID |
Phase I/II |
N/A |
|
|
indinavir + |
NIAID |
Phase I |
N/A |
|